[Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day--results of the use-results survey].

The Japanese journal of antibiotics Pub Date : 2014-06-01
Seiji Hori, Kazuhiro Uchino, Takuyuki Matsumoto, Hiroki Yamaguchi, Megumi Takahashi, Satoko Hamajima, Kaori Nukui, Hisano Eda, Akiko Shiina, Atsushi Takita, Naoki Yamanouchi, Masami Mizuno, Yukihiro Okutani
{"title":"[Study on the safety and efficacy of sitafloxacin at a dose of 100 mg once a day--results of the use-results survey].","authors":"Seiji Hori,&nbsp;Kazuhiro Uchino,&nbsp;Takuyuki Matsumoto,&nbsp;Hiroki Yamaguchi,&nbsp;Megumi Takahashi,&nbsp;Satoko Hamajima,&nbsp;Kaori Nukui,&nbsp;Hisano Eda,&nbsp;Akiko Shiina,&nbsp;Atsushi Takita,&nbsp;Naoki Yamanouchi,&nbsp;Masami Mizuno,&nbsp;Yukihiro Okutani","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from December 2011 to May 2013. In total, 1,186 case cards were collected from 226 medical institutions and 1,089 cases were subjected to a safety evaluation and 1,069 were subjected to an efficacy evaluation. The incidence of adverse drug reactions (ADRs) was 2.11% (23/1,089 cases) and no serious ADRs were observed. The major ADR was diarrhea at 1.10% (12/1,089 cases). Of these 12 cases, 10 cases developed symptoms within 4 days of treatment. All of them, except one case that could not be followed up, either recovered or improved. Nonsteroidal anti-inflammatory drugs of the phenyl acetate and propionate types, which require caution when coadministered with STFX, were used concomitantly by 17.6% (192/1,089 cases) of patients but no central nervous system ADRs were observed. The overall efficacy rate was 96.4% (1,030/1,069 cases) and by types of infections, it was 97.0% (387/399 cases) for respiratory tract infections, 96.7% (353/365 cases) for urinary tract infections, 94.7% (36/38 cases) for gynecological infections, 92.3% (132/143 cases) for otorhinolaryngological infections, 98.4% (122/124 cases) for dental and oral surgical infections. The efficacy rate in every category of site of infection exceeded 90%. The overall eradication rate was 94.4% (185/196 strains) including Gram-positive bacteria at 95.4% (62/65 strains), Gram-negative bacteria at 92.2% (94/102 strains), anaerobes at 100.0% (11/11 strains) and atypical bacteria at 100.0% (18/18 strains). In conclusion, this use-results survey confirmed that STFX 100 mg/day is an effective administration with no serious problems in its safety profile and efficacy rate of over 90% in every category of site of infection.</p>","PeriodicalId":22536,"journal":{"name":"The Japanese journal of antibiotics","volume":"67 3","pages":"175-91"},"PeriodicalIF":0.0000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Japanese journal of antibiotics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Sitafloxacin (STFX, Gracevit 50 mg, fine granules 10%), an oral quinolone antibacterial agent, was approved additionally for administration at a dose of 100 mg once a day in August 2011. A use-results survey on STFX 100 mg/day was performed from December 2011 to May 2013. In total, 1,186 case cards were collected from 226 medical institutions and 1,089 cases were subjected to a safety evaluation and 1,069 were subjected to an efficacy evaluation. The incidence of adverse drug reactions (ADRs) was 2.11% (23/1,089 cases) and no serious ADRs were observed. The major ADR was diarrhea at 1.10% (12/1,089 cases). Of these 12 cases, 10 cases developed symptoms within 4 days of treatment. All of them, except one case that could not be followed up, either recovered or improved. Nonsteroidal anti-inflammatory drugs of the phenyl acetate and propionate types, which require caution when coadministered with STFX, were used concomitantly by 17.6% (192/1,089 cases) of patients but no central nervous system ADRs were observed. The overall efficacy rate was 96.4% (1,030/1,069 cases) and by types of infections, it was 97.0% (387/399 cases) for respiratory tract infections, 96.7% (353/365 cases) for urinary tract infections, 94.7% (36/38 cases) for gynecological infections, 92.3% (132/143 cases) for otorhinolaryngological infections, 98.4% (122/124 cases) for dental and oral surgical infections. The efficacy rate in every category of site of infection exceeded 90%. The overall eradication rate was 94.4% (185/196 strains) including Gram-positive bacteria at 95.4% (62/65 strains), Gram-negative bacteria at 92.2% (94/102 strains), anaerobes at 100.0% (11/11 strains) and atypical bacteria at 100.0% (18/18 strains). In conclusion, this use-results survey confirmed that STFX 100 mg/day is an effective administration with no serious problems in its safety profile and efficacy rate of over 90% in every category of site of infection.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
【西他沙星100mg / d的安全性和有效性研究——使用-结果调查结果】。
西他沙星(STFX, Gracevit 50 mg,细颗粒10%)是一种口服喹诺酮类抗菌剂,于2011年8月被批准以100 mg /天一次的剂量额外给药。2011年12月至2013年5月对STFX 100 mg/d进行了使用结果调查。从226家医疗机构共收集了1186例病例卡,对1089例进行了安全性评价,对1069例进行了疗效评价。药物不良反应(adr)发生率为2.11%(23/ 1089),未见严重不良反应发生。主要不良反应为腹泻,占1.10%(12/ 1089)。在这12例病例中,10例在治疗4天内出现症状。除1例无法随访外,其余患者均恢复或好转。17.6%(192/ 1089例)的患者同时使用非甾体类抗炎药醋酸苯酯和丙酸酯类抗炎药,但未观察到中枢神经系统不良反应。总有效率为96.4%(1030 / 1069例),按感染类型分,呼吸道感染97.0%(387/399例)、尿路感染96.7%(353/365例)、妇科感染94.7%(36/38例)、耳鼻喉科感染92.3%(132/143例)、口腔外科感染98.4%(122/124例)。各类感染部位的有效率均超过90%。总根除率为94.4%(185/196株),其中革兰氏阳性菌95.4%(62/65株),革兰氏阴性菌92.2%(94/102株),厌氧菌100.0%(11/11株),非典型菌100.0%(18/18株)。总之,这项使用结果调查证实,STFX 100 mg/天是一种有效的给药,其安全性没有严重问题,在每种感染部位的有效率都超过90%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
[Carumonam]. [Cefroxadine]. Importance of prevention in pneumonia in elderly -Attempted use of macrolide therapy. High efficiency method of detection and isolation of neuraminidase inhibitor resistant influenza viruses by fluorescence sialidase imaging. The change of susceptibility of Streptococcus pneumoniae strains isolated from pediatric patients at Asahikawa Kosei Hospital between 2011 and 2015.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1